Skip to main content
. 2018 Mar 14;2018:9585614. doi: 10.1155/2018/9585614

Figure 4.

Figure 4

A general schematic outlining the structure of bivalent T cell engager (BiTE) antibodies. One end of the bispecific antibody is against a B cell tumor antigen (CD20), and the other end is specific against T cells (pMHC1 or CD3). The bivalent antibodies help direct T cells toward the vicinity of the tumor to aid in cytotoxic destruction of the neoplasm.